Volume 11, Issue 3 (Vol.11 No.3 Oct 2022)                   rbmb.net 2022, 11(3): 524-531 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Nazar Hasan Anber Z, Oead Mohammed Saleh B, Al-obidy M. Hepatocellular Damage and Severity of COVID-19 Infection in Iraqi Patients: A Biochemical Study. rbmb.net 2022; 11 (3) :524-531
URL: http://rbmb.net/article-1-916-en.html
Clinical Biochemistry, Department of Pharmacy, Baghdad College of Medical Sciences, Baghdad, Iraq.
Abstract:   (277 Views)

Background: Infection with COVID-19 can cause hepatic damages. Here, we aimed to examine the effect of COVID-19 infection on the serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin, and procalcitonin (PCT) concentrations as markers to evaluate the liver function.
 

Methods: In this study, 56 patients infected with COVID- 19 and 28 healthy controls was recruited in Private Nursing Home Hospital of the Medical City, Baghdad. Patients were subdivided according to disease severity into severe and non-severe groups.

Results: The results showed that the mean±SD value of serum AST activity and serum PCT concentrations were elevated significantly in severe group in comparison to healthy control, (p< 0.01, p< 0.001) respectively. Also, the mean ±SD value of serum ALT activity was higher in severe group compared to the healthy subjects and non-severe ones, significantly (p< 0.0001, p< 0.003) respectively. While the mean value of serum albumin concentration of severe patients and non-severe group were significantly decreased compared to healthy subjects. The receiver operating characteristic curve (ROC) revealed that ROC value of albumin (0.992) differentiates between non- severe infected patients and healthy subjects, while the ROC value of serum ALT activity (0.735) differentiates between severe COVID-19 patients and non- severe ones.
 

Conclusions: Changes of liver function parameters in COVID-19 patients were mild to moderate and measurement of serum ALT activity is the best biomarker in differentiation between non-severe patients and severe ones and albumin concentration is excellent in discrimination between patients and controls

Full-Text [PDF 220 kb]   (102 Downloads)    
Type of Article: Original Article | Subject: Biochemistry
Received: 2022/04/13 | Accepted: 2022/04/24 | Published: 2022/12/31

References
1. Pillaiyar T, Wendt LL, Manickam M, Easwaran M. The recent outbreaks of human coronaviruses: A medicinal chemistry perspective. Med Res Rev. 2021;41(1):72-135. [DOI:10.1002/med.21724] [PMID] [PMCID]
2. Ghahramani S, Tabrizi R, Lankarani KB, Kashani SMA, Rezaei S, Zeidi N, et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: A systematic review and meta-analysis. Eur J Med Res. 2020; 25(1):1-10. [DOI:10.1186/s40001-020-00432-3] [PMID] [PMCID]
3. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. [DOI:10.1016/j.jaut.2020.102433] [PMID] [PMCID]
4. Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141-1149. [DOI:10.1038/s41401-020-0485-4] [PMID] [PMCID]
5. Thomas S. The structure of the membrane protein of sars-cov-2 resembles the sugar transporter semisweet. Pathog Immun. 2020;5(1):342-63. [DOI:10.20411/pai.v5i1.377] [PMID] [PMCID]
6. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. [DOI:10.1038/s41586-020-2012-7] [PMID] [PMCID]
7. Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24(422):1-10. [DOI:10.1186/s13054-020-03120-0] [PMID] [PMCID]
8. Ali N. Relationship between COVID-19 Infection and Liver Injury: A Review of Recent Data. Front Med. 2020;7(458):1-6. [DOI:10.3389/fmed.2020.00458] [PMID] [PMCID]
9. Nardo AD, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID- 19. Liver Int. 2021;41(10:20-32. [DOI:10.1111/liv.14730] [PMID] [PMCID]
10. Moman RN, Gupta N, Varacallo M. Physiology, Albumin. StatPearls. Treasure Island (FL): StatPearls Publishing, 2020.
11. Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: Pathogenesis and Clinical Significance. JPEN J Parenter Enteral Nutr. 2019;43(2):181-193. [DOI:10.1002/jpen.1451] [PMID] [PMCID]
12. AlRawahi AN, AlHinai FA, Doig CJ, Ball CG, Dixon E, Xiao Z, Kirkpatrick AW. The prognostic value of serum procalcitonin measurements in critically injured patients: a systematic review. Crit Care. 2019;23(1):390. [DOI:10.1186/s13054-019-2669-1] [PMID] [PMCID]
13. Fan H, Cai J, Tian A, Li Y, Yuan H, Jiang Z, et al. Comparison of Liver Biomarkers in 288 COVID-19 Patients: A Mono-Centric Study in the Early Phase of Pandemic. Front Med (Lausanne). 2021;7:584888. [DOI:10.3389/fmed.2020.584888] [PMID] [PMCID]
14. Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study. Liver Int 2020; 40:1321-6. [DOI:10.1111/liv.14449] [PMID] [PMCID]
15. Lei P, Zhang L, Han P, Zheng C, Tong Q, Shang H et al. Liver injury in patients with COVID-19: clinical profiles, CT findings, the correlation of the severity with liver injury. Hepatology International 2020;14(5):733-742. [DOI:10.1007/s12072-020-10087-1] [PMID] [PMCID]
16. Qi X, Liu C, Jiang Z, Gu Y, Zhang G, Shao C, et al. Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injury. J Hepatol. 2020;73(2):455-458. [DOI:10.1016/j.jhep.2020.04.010] [PMID] [PMCID]
17. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8:420-422. [DOI:10.1016/S2213-2600(20)30076-X] [PMID]
18. Yang L, Wang W, Wang X, Zhao J, Xiao L, Gui W, et al. Creg in Hepatocytes Ameliorates Liver Ischemia/Reperfusion Injury in a TAK1-Dependent Manner in Mice. Hepatology. 2019;69(1):294-313. [DOI:10.1002/hep.30203] [PMID]
19. Zhang XJ, Cheng X, Yan ZZ, Fang J, Wang X, Wang W et al. An ALOX12-12-HETE-GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury. Nat Med. 2018,24(1):73- 83. [DOI:10.1038/nm.4451] [PMID]
20. Shokri Afra H, Amiri-Dashatan N, Ghorbani F, Maleki I, Rezaei-Tavirani M. Positive association between severity of COVID-19 infection and liver damage: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2020;13(4):292-304.
21. Huang J, Cheng A, Kumar R, Fang Y, Chen G, Zhu Y, Lin S. Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity. J Med Virol. 2020;92(10):2152-58. [DOI:10.1002/jmv.26003] [PMID] [PMCID]
22. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L. SARS-CoV-2 infection: The role
23. of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54: 62-75. [DOI:10.1016/j.cytogfr.2020.06.001] [PMID] [PMCID]
24. Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv, 2020. DOI: 10.1101/2020.02.03.931766. [DOI:10.1101/2020.02.03.931766]
25. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta. 2020;505:190-191. [DOI:10.1016/j.cca.2020.03.004] [PMID] [PMCID]
26. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents. 2020;56(2):106051. [DOI:10.1016/j.ijantimicag.2020.106051] [PMID] [PMCID]
27. Asghar MS, Haider Kazmi SJ, Khan NA, Akram M, Hassan M, Rasheed U, Ahmed Khan S. Poor Prognostic Biochemical Markers Predicting Fatalities Caused by COVID-19: A Retrospective Observational Study From a Developing Country. Cureus. 2020;12(8):e9575. [DOI:10.7759/cureus.9575]
28. Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci. 2020;24(6):3404-3410.
29. Falcão Gonçalves P, Menezes Falcão L, Duque Pinheiro I. Procalcitonin as Biomarker of Infection: Implications for Evaluation and Treatment. Am J Ther. 2017;24(3):e243-e249. [DOI:10.1097/MJT.0000000000000210] [PMID]
30. Grondman I, Pirvu A, Riza A, Ioana M, Netea MG. Biomarkers of inflammation and the etiology of sepsis. Biochem Soc Trans. 2020;48(1):1-14. [DOI:10.1042/BST20190029] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb